CLBT Cellebrite posts 186 percent year over year Q4 2025 revenue growth and edges past consensus EPS estimates Vertex Pharmaceuticals VRTX Fundamental Outlook Amid Recent Retail Investor Interest HERE Here Group Q4 2025 earnings vastly outperform analyst estimates as shares post modest gains today Is Grupo SIM stock worth allocating capital to 098 20260420 RCL Royal beats Q1 earnings estimates by 118 percent but stock slides LQDT Liquidity Services notches 159 percent Q1 2026 EPS beat shares climb 125 percent in daily trading Trading Day Market Downs as Investors Digest Legacy Education LGCY Stock Price Direction Insight Q1 2026 Profit Surprises Corvus CRVS Stock Build a Position Smart Money Exits 20260420